Skip to content
Clinical Trials – home
Therapeutic area

Nervous system disorders – page 47

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Insomnia+1

Recruiting

Study on Melatonin and Low-Dose Quetiapine for Patients with Psychiatric Disorders and Insomnia

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Melatonin
  • Sponsor:Psykiatrisk Center Kobenhavn

Migraine+2

Recruiting

Study on the Safety and Effectiveness of Atogepant for Preventing Episodic Migraine in Children and Teens Aged 6 to 17

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effects of Annual vs. Semi-Annual Ocrelizumab Infusions in Patients with Active Multiple Sclerosis After 2 Years of Initial Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Fondation A De Rothschild

Neuralgia

Recruiting

Study on Capsaicin Patch for Treating Chronic Neuropathic Pain in Children Aged 12-17

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Capsaicin
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Study on the Effectiveness of Botulinum Toxin A and Sodium Chloride for Patients with Trigeminal Neuralgia

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Region Hovedstaden

Migraine+2

Recruiting

Study on Long-term Safety and Tolerability of Atogepant for Children and Teens (Ages 6-17) with Migraine

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing Capsaicin Patch and Duloxetine for Patients with Chemotherapy-Induced Peripheral Neuropathy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capsaicin
  • Sponsor:Institut De Cancerologie De L Ouest

Medulloblastoma

Recruiting

Study on the Effectiveness of Bevacizumab and Drug Combination for Children with Recurrent or Progressive Medulloblastoma, Ependymoma, and ATRT

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab
  • Sponsor:Medical University Of Vienna

Comparison of ocrelizumab and rituximab treatment in adults with active relapsing-remitting multiple sclerosis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Helse Bergen HF

Study on ONC201 and Everolimus with Radiotherapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Other Diffuse Midline Gliomas in Children, Adolescents, and Adults

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Institut Gustave Roussy

Study on the Effect of Vitamin C and Microcrystalline Cellulose on Reducing Complex Regional Pain Syndrome in Patients Undergoing Upper Limb Surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:L-Ascorbic Acid
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Study on Treating Status Epilepticus in Seniors Using Levetiracetam and Valproate Semisodium

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Levetiracetam
  • Sponsor:Universitaet Leipzig

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.